TY - JOUR
AU - 
AB - Reactions 426 - 7 Nov 1992 Acute proliferative retinopathy in premature neonates?: incidence study Surfactant replacement therapy with Curosurf (Rm) does not increase the risk of proliferative retinopathy of prematurity when used in very-low-birthweight preterm babies with severe respiratory distress syndrome according to a study conducted by UK researchers. Over a 5-year period, 76 preterm neonates (mean gestational age 27.6 weeks) with respiratory distress syndrome were treated with a single dose of intratracheal Curosurf (Rm) (equivalent to 100-200 mg/kg phospholipid) 2-31 hours after birth; some neonates also received 1-2 further doses of 100 mg/kg. Ophthalmological examinations were conducted until 36 weeks post-menstrual age or until ophthalmic signs disappeared. 62 neonates survived until hospital discharge. Of the 6/9 neonates weighing >= 1.5kg at birth who underwent ophthalmological examination, none developed retinopathy. 49/53 neonates weighing < 1.5 kg were examined and 14 (29%) had retinopathy of stage I (n = 7), II (4), III (2) or IV (1). This incidence of retinopathy of prematurity is similar to that observed in very-low-birthweight neonates who do not receive surfactant therapy Tubman TRJ, et al. Surfactant replacement therapy and the prevalence of acute retinopathy of prematurity. Biology of the Neonate 61 (Suppl. 1): 54-58, 
TI - Surfactants
JF - Reactions Weekly
DO - 10.2165/00128415-199204260-00058
DA - 2013-01-22
UR - https://www.deepdyve.com/lp/springer-journals/surfactants-TbJRUA6MDb
SP - 12
EP - 12
VL - 426
IS - 1
DP - DeepDyve
ER -